Hoya - Myopia Management at International Myopia Conference 2022

HOYA Vision Care Reveals Latest Insights to Advance Myopia Management at International Myopia Conference 2022 HOYA’s evidence-based approach for successful myopia management helps eye care professionals make informed clinical decisions SYDNEY – 08 Sept. 2022 – HOYA Vision Care, a leader in optical technology innovation, participated as an official diamond sponsor in the International Myopia Conference (IMC) held 4-7 September 2022 in Rotterdam, The Netherlands. During the conference, HOYA hosted a myopia symposium where experts shared their latest findings of the clinical application of the MiYOSMART spectacle lens and its role in myopia management.

Under the theme –The Latest Insights to Advance Myopia Management - renowned key opinion leaders shared new European data and discussed topics including emmetropic eye growth, combination treatment as well as relative peripheral refraction (RPR).

Dr. Andrea Lembo of the University Hospital San Giuseppe Multimedica in Milan, Italy shared the results of a clinical application of the MiYOSMART spectacle lens in combination with 0.01% Atropine drops in European myopic children and adolescents.1 The results demonstrated that over one-year, axial elongation and myopia progression were reduced with maximum effect using the combination treatment.1 Prof. Hakan Kaymak of the Internationale Innovative Ophthalmochirurgie in Duesseldorf, Germany presented the findings of his study on axial length growth under treatment with MiYOSMART spectacle lenses. The data of German children wearing MiYOSMART spectacle lenses reconfirmed previous clinical study results.1 Further findings showed that children adapt very well to MiYOSMART spectacle lenses with no safety concerns even in combination with low-dose atropine.1 In addition, Professor Carly Lam of The Hong Kong Polytechnic University shared how myopia control effect may be influenced by baseline relative peripheral refraction in children wearing the MiYOSMART spectacle lens with D.I.M.S. Technology.1 The results showed that myopia control effect was stronger in children with baseline hyperopic RPR than in children with baseline myopic RPR.1 “We are very pleased to be able to share the latest evidence-based approach to myopia management at IMC 2022,” said May Zhang, Global Head of Professional Affairs. “HOYA Vision Care continues to be a leader in addressing myopia in children and championing new practices like the successful combination treatment of the MiYOSMART spectacle lens and Atropine drops as well as continued

support of clinical studies in multiple countries to help eye care professionals make informed decisions.”

Since its launch in 2018, MiYOSMART is available in 28 markets, including Australia and New Zealand, with over two million spectacle lenses purchased by parents around the world.2 PRODUCT DISCLAIMER – MiYOSMART has not been approved for myopia management in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S. 1

Kaymak H, Lembo A, Lam CSY. HOYA Vision Care Myopia Symposium " New Insights to

Advance Myopia Management": Axial length growth under therapy with MiYOSMART spectacle lenses; A comparison of myopia control in European children with Defocus Incorporated Multiple Segments (DIMS) spectacles, atropine, and combined DIMS/atropine; Myopia control effect is influenced by baseline relative peripheral refraction in children wearing Defocus Incorporated Multiple Segments (DIMS) spectacle lenses. International Myopia Conference (IMC) 2022, September 4, Rotterdam, The Netherlands.

2

Based on number of MiYOSMART lenses sold per Hoya sales data on file as of June 2022. ###

About HOYA Vision Care For over 60 years, HOYA Vision Care has been a passionate and global leader in optical technology innovation. As a manufacturer of high quality, high performing eyeglass lenses, HOYA continues to drive optical technology innovation with the aim of finding the best vision care solutions for Eye Care Professionals. The company supplies lenses in 52 countries with a network of over 18,000 employees and 45 laboratories around the globe.

About HOYA Founded in 1941 in Tokyo, Japan, HOYA Corporation is a global technology and med-tech company and a leading supplier of innovative high-tech and medical products. HOYA’s divisions and business units research and develop products utilized in the healthcare and information technology fields. In the healthcare field, we provide medical device products such as eyeglasses, medical endoscopes, contact and intraocular lenses, orthopedic implants, surgical/therapeutic devices and medical device reprocessing and disinfection solutions. In the information technology field, we provide products such as optical lenses, photomasks and blanks used in the manufacturing process for semiconductor and LCD/OLED devices, text to speech, human resources and other software solutions and critical components for the mass memory and cloud storage industries. With over 150 offices and subsidiaries worldwide, HOYA currently employs a multinational workforce of 37,000 people.

For further information (not for publication) contact: Ulli Hentschel Hoya National Training & Development E: ulli.hentschel@hoya.com

M: 0498 016 278 www.hoyavision.com.au Follow HOYA Vision Care: